FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220742008> ?p ?o ?g. }

• W4220742008 endingPage "S201" @default.
• W4220742008 startingPage "S200" @default.
• W4220742008 abstract "As the SARS-CoV-2 virus, the cause of COVID-19, emerged in early 2020 and quickly spread across the globe, clinical molecular genetics laboratories experienced a dramatic drop in samples referred for clinical testing as non-critical healthcare appointments were postponed. These laboratories, utilizing years of expertise in a field of rapidly evolving new technologies and high throughput testing, as well as clinical technologists trained in high-complexity testing, large genetics laboratories stepped in the fill the gap, a measure that kept laboratories running and staff employed. Our expertise in high-throughput high-complexity led from requests to perform testing in our genomics laboratory to building new laboratories in both the United Sates (US) and the United Kingdom (UK). These efforts resulted in building three laboratories from an empty space to a functioning, staffed clinical laboratory in approximately eight weeks. In total, these laboratories have employed over 1200 individuals (∼550 US and ∼700 UK). To date, these laboratories have performed over 10 million SARS-CoV-2 assays. Initial challenges included navigating state, federal, and country regulations and rapidly training a large clinical staff while ensuring optimal assay performance. As the pandemic continued, unpredictable decreases and surges in case numbers led to uncertainty in program longevity and staffing needs creating operational challenges. Clinical testing in the US is governed by the Clinical Laboratory Improvement Amendments (CLIA), which provide very specific requirements for personnel, training, proficiency testing and the quality management system. However, high complexity molecular testing for a viral target could fall into the CLIA category of general chemistry (as does molecular genetic testing) or microbiology, subcategory virology. The category chosen has dramatic effects on the specific experience required for technologists, supervisors and the laboratory director. Outside the US, laboratory requirements are dictated by accepted best practices and accrediting agencies, rather than specific laws, sometimes making it difficult to know what requirements need to be met. In the US, regulatory guidance has been dynamic. At the beginning of the pandemic, laboratories were required to use an assay with Food and Drug Administration (FDA) Emergency Use Authorization (EUA) or submit an EUA for their Laboratory Developed Test (EUA). In the fall of 2020, the FDA stopped requiring and declined to review new EUA applications for LDT assays. In November 2021 EUA submissions once again were required for any assay in use without an EUA. This has put unpresented pressure on laboratory operations to identify and hire qualified individuals to navigate the assay validation and subsequent assay management requirements. The FDA has approved EUAs with a wide range of assay sensitivity, ranging from 20 copies/ ml to several thousand copies/ ml. This wide range of assays used by the laboratories led to some unexpected outcomes. For example, individuals who tested positive the laboratory tested negative by another less sensitive assay, resulting in the perception of discrepant results. Further, vaccinated people testing positive, albeit with indication of a low viral load, was also unexpected. The high sensitivity of the assay with lowest copy detection allows the diagnosis of more individuals than less sensitivity assays, which is critical in stopping the spread of a virus that can be asymptomatic. An approach for cost saving is pooling of samples. When case numbers surge, as occurred with the spread of the SARS-CoV-2 Delta variant, a pooling approach is no longer efficient, therefore, a permanent shift to a pooling approach is not feasible. In conclusion, our experience with high-throughput sequencing is allowing us to pivot quickly to viral genome sequencing, which is proving critical to understanding and combating this pandemic. Rare metabolic diseases, intellectual disabilities and hereditary cancer syndromes will always still need attention and continuous innovation but the innovation in genomics has greatly facilitated the much needed scaling of testing facilities for SARS-CoV2. We will need to learn to balance these activities and continue to support testing needs for these in addition to emerging diseases." @default.
• W4220742008 created "2022-04-03" @default.
• W4220742008 creator A5006682362 @default.
• W4220742008 creator A5022953863 @default.
• W4220742008 creator A5040773471 @default.
• W4220742008 creator A5041071963 @default.
• W4220742008 creator A5047448597 @default.
• W4220742008 creator A5070550078 @default.
• W4220742008 creator A5074990882 @default.
• W4220742008 creator A5086919988 @default.
• W4220742008 creator A5087558368 @default.
• W4220742008 date "2022-03-01" @default.
• W4220742008 modified "2023-10-03" @default.
• W4220742008 title "eP321: Extending and adapting the functions of genetic laboratories in the continuing COVID pandemic–challenges and successes" @default.
• W4220742008 doi "https://doi.org/10.1016/j.gim.2022.01.356" @default.
• W4220742008 hasPublicationYear "2022" @default.
• W4220742008 type Work @default.
• W4220742008 citedByCount "0" @default.
• W4220742008 crossrefType "journal-article" @default.
• W4220742008 hasAuthorship W4220742008A5006682362 @default.
• W4220742008 hasAuthorship W4220742008A5022953863 @default.
• W4220742008 hasAuthorship W4220742008A5040773471 @default.
• W4220742008 hasAuthorship W4220742008A5041071963 @default.
• W4220742008 hasAuthorship W4220742008A5047448597 @default.
• W4220742008 hasAuthorship W4220742008A5070550078 @default.
• W4220742008 hasAuthorship W4220742008A5074990882 @default.
• W4220742008 hasAuthorship W4220742008A5086919988 @default.
• W4220742008 hasAuthorship W4220742008A5087558368 @default.
• W4220742008 hasBestOaLocation W42207420081 @default.
• W4220742008 hasConcept C142724271 @default.
• W4220742008 hasConcept C159110408 @default.
• W4220742008 hasConcept C2777512617 @default.
• W4220742008 hasConcept C2779134260 @default.
• W4220742008 hasConcept C3008058167 @default.
• W4220742008 hasConcept C509550671 @default.
• W4220742008 hasConcept C524204448 @default.
• W4220742008 hasConcept C71924100 @default.
• W4220742008 hasConcept C89623803 @default.
• W4220742008 hasConceptScore W4220742008C142724271 @default.
• W4220742008 hasConceptScore W4220742008C159110408 @default.
• W4220742008 hasConceptScore W4220742008C2777512617 @default.
• W4220742008 hasConceptScore W4220742008C2779134260 @default.
• W4220742008 hasConceptScore W4220742008C3008058167 @default.
• W4220742008 hasConceptScore W4220742008C509550671 @default.
• W4220742008 hasConceptScore W4220742008C524204448 @default.
• W4220742008 hasConceptScore W4220742008C71924100 @default.
• W4220742008 hasConceptScore W4220742008C89623803 @default.
• W4220742008 hasIssue "3" @default.
• W4220742008 hasLocation W42207420081 @default.
• W4220742008 hasLocation W42207420082 @default.
• W4220742008 hasOpenAccess W4220742008 @default.
• W4220742008 hasPrimaryLocation W42207420081 @default.
• W4220742008 hasRelatedWork W2899084033 @default.
• W4220742008 hasRelatedWork W3119540162 @default.
• W4220742008 hasRelatedWork W3147359336 @default.
• W4220742008 hasRelatedWork W3162081874 @default.
• W4220742008 hasRelatedWork W3177949192 @default.
• W4220742008 hasRelatedWork W3193878481 @default.
• W4220742008 hasRelatedWork W3199606337 @default.
• W4220742008 hasRelatedWork W3203798056 @default.
• W4220742008 hasRelatedWork W4205415952 @default.
• W4220742008 hasRelatedWork W4313474620 @default.
• W4220742008 hasVolume "24" @default.
• W4220742008 isParatext "false" @default.
• W4220742008 isRetracted "false" @default.
• W4220742008 workType "article" @default.